Listen to Dr. Steven Feldman as he discusses methods to improve adherence and outcomes for patients with psoriasis.
CLICK HERE to earn 1 CME/CNE/CPE credit now!
Coalition of Rheumatology Educators
Live Events
Online Courses
On-Demand Webcast:
Optimizing Osteoporosis Outcomes Following Fragility Fracture 2013: A Blueprint for Orthopedic Surgeons and Orthopedists
(CME, CNE)
Case Study:
Case 1: Sara is a 23-year-old Hispanic waitress with a history of plaque psoriasis which has recently been unusually aggravated and is not responding to her typical treatment
(CME, CNE)
Case Study:
Case 2: Jennifer is a 54-year-old Caucasian teacher with plaque psoriasis who was recently diagnosed with polyarthritis involving her hand joints
(CME, CNE)
Case Study:
Case 3: David is a 48-year-old African American with plaque psoriasis that has never be under control while using topical steroids so alternative treatments are being considered
(CME, CNE)
News
05/22/2013
Enzyme-activating Antibodies Revealed as Marker for Most Severe Form of RA
In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe cases of the disease, the immune system makes a unique subset of antibodies that have a disease-promoting role.
Read MoreCORE BLOG POSTS
by Sergio Schwartzman on 05/22/2013
It is well known that rheumatoid arthritis (RA) can affect the lung. Pleuritis, interstitial lung disease (ILD) and fibrosis, vasculitis, pulmonary nodules, and Caplan’s syndrome have been described.
by Marc Cohen on 05/21/2013
Given the recent enthusiasm for triple disease-modifying antirheumatic drug (DMARD) therapy for the treatment of rheumatoid arthritis (RA), one wonders what happened to rheumatologists’ love of the tumor necrosis factor inhibitors (TNFi’s).
by Sergio Schwartzman on 05/21/2013
It is now indisputable that patients with RA have a significant cardiovascular (CV) risk and that indeed one of the most common causes of death in patients with this disease is a CV event.
by Gregg Silverman on 05/01/2013
With the introduction of therapeutic biologic agents for rheumatoid arthritis (RA), our chances for inducing dramatic clinical responses have become greatly enhanced. Yet, the immune system is a complex, layered, and interconnected system.
by Sergio Schwartzman on 04/24/2013
The concept of “treat to target” has gleaned significant attention in the management of patients with rheumatoid arthritis (RA); there are currently some early rheumatologist adopters of this philosophy.
CORE Registration
